City Therapeutics raises $230M in upsized Nasdaq IPO

City Therapeutics (CTY) dosed the first participant in a Phase 1 trial for CITY-RBP4, a treatment for Stargardt disease. The study will assess safety and drug activity, with initial data expected in mid-2027. CITY-RBP4 aims to reduce RBP4 production, limiting vitamin A transport to the eye. The company has two other programs in clinical testing.

City Therapeutics dosed the first participant in its Phase 1 trial of CITY-RBP4, a treatment for Stargardt disease. The trial will assess safety and efficacy, with initial data expected in mid-2027. CITY-RBP4 aims to slow retinal damage by reducing vitamin A delivery to the eye. This is the company's second program in clinical development.

CITY THERAPEUTICS, INC. (CTY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in S

Jefferies initiated City Therapeutics (NASDAQ:CTY) with a buy rating and $32 price target, citing its RNAi platform and lead programs. The stock, trading at $18.67, has declined 16.7% over six months. Jefferies highlighted potential catalysts and strong cash position. The company's IPO saw high demand, with limited share allocation due to oversubscription.

City Therapeutics (CTY) completed its upsized IPO, raising $230M by selling 12.8M shares at $18 each. The company plans to use the proceeds to advance its RNAi programs, with future catalysts tied to clinical and regulatory milestones.

City Therapeutics, a biotech company, raised $230 million in its upsized IPO, selling 12.78 million shares at $18 each. The company's stock began trading on Nasdaq under the ticker CTY. City Therapeutics focuses on RNA interference therapeutics for diseases like thromboembolic conditions and retinal diseases.